A Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma (NCT07532265)
A Phase 2 Randomized Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Three Doses of Frevecitinib (KN-002) in Patients With Severe Asthma
🩺 Plain-English Summary (8th-Grade Level)
A Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) Over a 12-Week Treatment Period in Patients With Severe Asthma Not Controlled With Medium to High Dose ICS/LABA
Who can join: Review the eligibility criteria below.
Location: Research site — Lancaster, California
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (14 Sites)
- Research site — Lancaster, California
- Research site — San Jose, California
- Research site — Brandon, Florida
- Research site — Miami, Florida
- Research site — Tampa, Florida
- Research site — Chicago, Illinois
- Research site — Kansas City, Missouri
- Research site — Charlotte, North Carolina
- Research site — Pittsburgh, Pennsylvania
- Research site — Rock Hill, South Carolina
- Research site — Dallas, Texas
- Research site — Houston, Texas
- Research site — San Antonio, Texas
- Research site — Williamsburg, Virginia
📞 Contact the Study Coordinator
Phone: (855) 818-2289
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Severe Asthma
- A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR) — Bakersfield, California
- Using NLP and Neural Networks to Autonomously Identify Severe Asthma and Determine Study Eligibility in a Large Healthcare System — San Diego, California
- Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. — Palmdale, California
- Tezepelumab in the Treatment of Emergency Room Asthma in Adults (TERAA) — Edmonton, Alberta
- A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2) — Bakersfield, California
- International Severe Asthma Registry: Canadian Cohort — Edmonton, Alberta
Explore by condition: All Severe Asthma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.